Status:

RECRUITING

Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory Problems

Lead Sponsor:

Rotman Research Institute at Baycrest

Conditions:

Mild Cognitive Impairment (MCI)

Subjective Cognitive Decline (SCD)

Eligibility:

All Genders

55-85 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol in combination with cognitive training can improve cognitive abilities in older...

Detailed Description

This study will examine the effects of combining cognitive remediation with accelerated intermittent theta burst stimulation (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to...

Eligibility Criteria

Inclusion

  • 55 - 85 years of age (on the day of randomization)
  • are male or post-menopausal female
  • have a diagnosis of mild cognitive impairment (MCI) based on Montreal Cognitive Assessment score \< 26 or where available, results from clinical neuropsychological assessment, OR subjective memory concerns and first degree relative, living or deceased, with a probable or confirmed diagnosis of AD
  • score 24 or higher on the Mini Mental State Examination (MMSE)
  • are willing to provide informed consent
  • are able to follow the treatment schedule
  • are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)
  • have a satisfactory safety screening questionnaire for TMS

Exclusion

  • have a metal plate in their head(such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe.
  • have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures
  • have a cardiac pacemaker
  • have an implanted medication pump
  • have a central venous line
  • have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia
  • have a history of substance abuse in the last 6 months
  • have a history of stroke or other brain lesions
  • have a personal history of epilepsy
  • have a family history of epilepsy
  • are a pregnant or breast-feeding woman
  • have a history of abnormal MRI of the brain
  • have untreated hypo- or hyper-thyroidism
  • have unstable medical condition(s)
  • have any other known contraindications to TMS
  • are on unstable doses of any psychotropic medication such as antidepressants, antipsychotic, mood stabilizers or memory enhancing medications
  • regularly use benzodiazepines or other hypnotics within 2 weeks of randomization

Key Trial Info

Start Date :

November 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 15 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT07212504

Start Date

November 15 2025

End Date

March 15 2027

Last Update

October 28 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rotman Research Institute at Baycrest

Toronto, Ontario, Canada, M6A 2E1